[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-induced-nausea-and-vomiting\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-induced-nausea-and-vomiting":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,63,86,115,141,169,193,221,245,272],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100630070","phase-4-an-exploratory-study-on-efficacy-and-safety-of-fosaprepitant-and-palonosetron-hydrochloride-for-injection-in-preventing-cinv-from-multi-agent-hec-100630070",false,"NCT07482891","An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC","An Exploratory Study on the Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Highly Emetogenic Multi-Agent Chemotherapy","Inclusion Criteria:\n\n* Aged 18-75 years, any gender, voluntarily signed informed consent form (ICF), with good compliance;\n* Histologically or cytologically confirmed malignant solid tumour;\n* No prior exposure to any chemotherapeutic agents;\n* First-time participants with malignant solid tumours scheduled to receive a treatment regimen based on multi-day HEC chemotherapy (HEC refers to the risk of anti-tumour drug-induced nausea and vomiting as defined in the 2023 Edition of the Chinese Guidelines for the Prevention and Treatment of Nausea and Vomiting Associated with Anti-tumour Therapy; 'multi-day' denotes each chemotherapy cycle lasting at least 3 days);\n* No impairment in speech, hearing, or comprehension;\n* Expected survival ≥ 3 months;\n* ECOG : 0-1;\n* Organ function must be adequate and meet the following criteria:\n\n  1. Neutrophil count ≥ 1.5 × 10⁹\u002FL;\n  2. Haemoglobin ≥ 90 g\u002FL;\n  3. Platelet count ≥ 100 × 10⁹\u002FL;\n  4. Total bilirubin ≤ 1.5 × upper limit of normal (ULN);\n  5. In patients without known liver metastases, aspartate aminotransferase ≤ 2.5 × ULN and\u002For alanine aminotransferase ≤ 2.5 × ULN (for patients with liver metastases, may be relaxed to ≤ 5 × ULN);\n  6. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 ml\u002Fmin;\n  7. Electrocardiogram: QTc ≤ 450 ms (males), QTc ≤ 470 ms (females);\n  8. Echocardiogram: LVEF (left ventricular ejection fraction) ≥ 50%.\n* Female subjects of childbearing potential, and male subjects with female partners of childbearing potential, must use one form of effective contraception from the time of signing the informed consent form until 6 months after the last dose (see Appendix). Female subjects of childbearing potential must have a negative blood pregnancy test within 72 hours prior to enrolment and must not be breastfeeding.\n\nExclusion Criteria:\n\n* Subjects with symptomatic brain metastases or any symptoms suggestive of brain metastases or intracranial hypertension;\n* Subjects who have received radiotherapy within 7 days prior to enrolment, extensive radiotherapy (e.g., whole-chest or whole-abdomen radiotherapy) within 3 months prior to enrolment, local palliative radiotherapy (e.g., for bone or lymph node metastases) within 1 month prior to enrolment, or who are scheduled to undergo any radiotherapy during the study period;\n* Administration within 2 days prior to enrolment of medications with potential antiemetic effects: first-generation 5-HT3 receptor antagonists (e.g., ondansetron), phenothiazines (e.g., prochlorperazine), butyrophenones (e.g., haloperidol), benzamides (e.g., metoclopramide), domperidone, cannabinoids, traditional Chinese medicines with potential antiemetic effects, scopolamine, or secloperazine;\n* Initiation of benzodiazepine or opioid therapy within 2 days prior to enrolment (excluding zolpidem, temazepam, or midazolam administered alone daily);\n* Subjects who commenced morphine use within 7 days prior to enrolment (excluding those on stable doses);\n* Systemic corticosteroid therapy (including but not limited to dexamethasone, hydrocortisone, methylprednisolone, or prednisolone) or sedating antihistamines (e.g., diphenhydramine) administered within 7 days prior to enrolment (Note: Single-dose steroids for contrast allergy prophylaxis, or topical\u002Finhaled administration are permitted);\n* Use of palonosetron within 14 days prior to enrolment;\n* Use of NK-1 receptor antagonists within 28 days prior to enrolment;\n* Vomiting and\u002For retching, nausea occurring within 24 hours prior to enrolment;\n* Presence of poorly controlled serosal effusions, including pleural effusion, ascites, pericardial effusion (exclusion may be waived if controlled by treatment and stable for ≥2 weeks);\n* Severe cardiovascular disease within 3 months prior to enrolment, including but not limited to acute myocardial infarction, unstable angina pectoris, significant valvular or pericardial disease, history of ventricular tachycardia, symptomatic chronic heart failure (New York Heart Association \\[NYHA\\] Class II to IV), or history of severe cardiac conduction abnormalities (e.g., torsades de pointes ventricular tachycardia);\n* Concurrent active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 10⁴ copies\u002FmL), active hepatitis C (HCV-Ab positive with HCV-RNA ≥ ULN), known acquired immunodeficiency syndrome (AIDS) or HIV-positive status, or syphilis-positive status;\n* Concurrent conditions precluding dexamethasone administration, such as active infections (e.g., pneumonia) or uncontrolled conditions (e.g., diabetic ketoacidosis, intestinal obstruction);\n* Known contraindications and\u002For allergies to study medications;\n* Participation in another clinical trial within 30 days prior to enrolment (as determined by the use of study medication);\n* Subjects deemed by the investigator to have other conditions rendering them unsuitable for this study.","ALL","18 Years","75 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This prospective, multicenter, non-comparative, open-label trial design aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by hyperemetic chemotherapy (HEC) over multiple days. Eligible subjects were screened and assigned to Arm 1 or Arm 2 according to medical protocol. Arm 1: Fosrolapitant and Palonosetron Hydrochloride for Injection + Dexamethasone + Olanzapine; Arm 2: Fosrolapitant and Palonosetron Hydrochloride for Injection + Dexamethasone. Study drug administration commenced within 48 hours post-randomization, with follow-up visits and examinations completed as per protocol.",[27],"Chemotherapy-induced Nausea and Vomiting","RECRUITING","2026-04-29",{"date":31,"type":32},"2026-04-30","ACTUAL",{"date":34,"type":32},"2026-03-10",{"date":36,"type":21},"2026-12-31",{"name":38,"class":39},"Shanghai 6th People's Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":4},"100617728","effect-of-foot-reflexology-on-chemotherapy-induced-nausea-and-vomiting-in-breast-cancer-patients-100617728","NCT07322393","Effect of Foot Reflexology On Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients","Effect of Foot Reflexology On Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\nBreast Cancer patients aged \\>18 Patients receiving chemotherapy in curative setting\n\nExclusion Criteria:\n\nPatients with paraplegia. Patients with skin ulcers or wounds. Patients with psychiatric conditions. Patients with foot fractures and varicose veins. Patients with GIT and Liver Cancer","FEMALE",{"count":50,"type":21},50,[52],"NA","This study aims to evaluate the effect of foot reflexology on chemotherapy-induced nausea and vomiting in breast cancer patients. Nausea and vomiting are common side effects of chemotherapy and can negatively affect patients' comfort and quality of life. Foot reflexology is a non-invasive complementary therapy that involves applying pressure to specific points on the feet. The study will compare patients who receive foot reflexology along with standard care to those who receive standard care alone, to determine whether foot reflexology helps reduce the severity of nausea and vomiting during chemotherapy.",[27],"NOT_YET_RECRUITING",{"date":31,"type":32},{"date":58,"type":21},"2026-06-01",{"date":60,"type":21},"2026-09-01",{"name":62,"class":39},"University of Health Sciences Lahore",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":17,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100525363","effect-of-guided-imagery-on-chemotherapy-related-nausea-and-vomiting-100525363","NCT06120764","Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting","Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting in Pediatric Oncology Patients: a Randomized Controlled Trial","Inclusion Criteria:\n\n* 7 to 18 years old,\n* who will receive intravenous chemotherapy,\n* no cognitive or neurological disease that would prevent communication,\n* receiving a chemotherapy protocol with a high or moderate emetogenic effect according to the MASCC\u002FESMO Antiemetic Guideline Classification,\n* no verbal, visual and auditory communication disabilities (ability to speak Turkish, no mental deficiency),\n* children whose parents and themselves volunteered to participate in the study\n\nExclusion Criteria:\n\n* Children receiving radiotherapy,\n* taking ginger powder or vitamins to reduce nausea,\n* children who did not want to participate in the study","7 Years",{"count":72,"type":21},40,[52],"The goal of this randomized controlled study is to assess the effect of guided imagery on chemotherapy-related nausea and vomiting in pediatric oncology patients.\n\nParticipants will receive either guided imagery+routine care or routine care. The researchers will compare nausea and vomiting and vital signs between groups.",[27,76],"Pediatric Cancer","2026-04-27",{"date":79,"type":32},"2026-05-01",{"date":81,"type":32},"2023-11-10",{"date":83,"type":21},"2026-10-30",{"name":85,"class":39},"Baskent University",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100503698","serious-gaming-for-chemotherapy-induced-nausea-and-vomiting-100503698","NCT05838638","Serious Gaming for Chemotherapy-induced Nausea and Vomiting","Serious Gaming for Chemotherapy-induced Nausea and Vomiting in Older Adults With Cancer: A Randomized Clinical Trial","Inclusion Criteria:\n\n* age 60 or older\n* newly diagnosed with cancer\n* treatment with any chemotherapeutic agent of moderate or high emetic potential\n* on a 2, 3 or 4 week treatment cycle\n* proficient in English\n* has a telephone\n\nExclusion Criteria:\n\n* previous diagnosis and\u002For treatment for cancer\n* end stage disease with less than 6 months to live\n* visually or hearing impaired without corrective device","60 Years",{"count":95,"type":21},610,[52],"The purpose of this study is to examine the effectiveness of a technology-based intervention for managing nausea and vomiting in older adults with cancer. Participants will be randomized to either an intervention or control group. Outcomes such as symptom severity, quality of life, and resource use will be examined.",[99,27],"Neoplasms",[101,102,103,104,105,106],"aged","digital technology","nausea","neoplasm","Drug related side effects and adverse reactions","self-management",{"date":79,"type":32},{"date":109,"type":32},"2023-06-09",{"date":111,"type":21},"2027-06-30",{"name":113,"class":39},"University of Central Florida",2,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":114},"100634475","the-effect-of-stress-ball-on-nausea-anxiety-and-fatigue-in-patients-with-stomach-cancer-100634475","NCT07540169","The Effect of Stress Ball on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer","The Effect of Stress Balls on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer","Inclusion Criteria:\n\n* Between the ages of 18-80\n* Those who agree to participate in the study\n* Those without motor skill loss\n* Patients diagnosed with stomach cancer\n* Patients with hand-arm orientation skills\n\nExclusion Criteria:\n\n* Patients with loss of motor skills\n* Patients who wish to withdraw from the study","80 Years",{"count":124,"type":21},52,[52],"In this study, we will observe the effects of the Stress Ball.",[128,27,129],"Stomach Cancer","Fatigue",[131],"Stress Ball","2026-04-16",{"date":134,"type":32},"2026-04-20",{"date":136,"type":32},"2025-10-15",{"date":138,"type":21},"2026-05-24",{"name":140,"class":39},"Yuzuncu Yil University",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":22,"phases":150,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":40},"100584216","vomiting-prevention-in-children-with-cancer-100584216","NCT06886451","Vomiting Prevention in Children With Cancer","Prevention of Vomiting in Pediatric Oncology Inpatients Using Machine Learning","Inclusion Criteria:\n\n* All pediatric patients admitted to the oncology service at SickKids\n\nExclusion Criteria:\n\n* Pediatric patients admitted to the oncology service at SickKids that are discharged prior to prediction time",{"count":149,"type":21},1332,[52],"The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients.\n\nThe main questions it aims to answer are whether an ML model predicting the risk of vomiting within the next 96 hours will:\n\nPrimary\n\n1\\. Reduce the proportion with any vomiting within the 96-hour window\n\nSecondary\n\n1. Reduce the number of vomiting episodes\n2. Increase the proportion receiving care pathway-consistent care\n3. Impact on number of administrations and costs of antiemetic medications\n\nNewly admitted participants will have a ML model predict the risk of vomiting within the next 96 hours according to their medical admission information. The prediction will be made at 8:30 AM following admission. Pharmacists will be charged with bringing information about patients' vomiting risk to the attention of the medical team and implementing interventions.",[153,154,76],"Chemotherapy Induced Nausea and Vomiting","Quality of Life (QOL)",[156,157,158,159],"Vomiting","Machine learning","Quality of life","Pediatric oncology","2026-03-03",{"date":162,"type":32},"2026-03-05",{"date":164,"type":32},"2025-03-18",{"date":166,"type":21},"2027-03-18",{"name":168,"class":39},"The Hospital for Sick Children",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":176,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":183,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":40},"100589147","this-study-will-investigate-the-effectiveness-of-peppermint-oil-inhalation-in-reducing-the-intensity-and-frequency-of-acute-nausea-and-vomiting-among-cancer-patients-undergoing-chemotherapy-chemotherapy-induced-nausea-and-vomiting-cinv-are-among-the-most-distressing-side-effects-experienced-by-pa-100589147","NCT06950632","This Study Will Investigate the Effectiveness of Peppermint Oil Inhalation in Reducing the Intensity and Frequency of Acute Nausea and Vomiting Among Cancer Patients Undergoing Chemotherapy. Chemotherapy-induced Nausea and Vomiting (CINV) Are Among the Most Distressing Side Effects Experienced by pa","Effect of Peppermint Oil Inhalation on Intensity and Frequency of Acute Nausea and Vomiting in Cancer Patients Receiving Chemotherapy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* • Participants undergoing chemotherapy in the outpatient oncology department of Jinnah Hospital Lahore.\n\n  * Participants ages 20-50 years.\n  * Participants of Both genders' male and female.\n  * Participants who have undergone under one cycle of chemotherapy.\n  * Participants who can understand and comprehend Urdu and Punjabi language\n\nExclusion Criteria:\n\n* Participants who are allergic to peppermint products.\n* Participants who have any psychiatric illness.\n* Participants diagnosed with any respiratory illness.\n* Participants who have vomiting due to any ailment other than chemotherapy.\n* Participants with Gastro-intestinal and Hepatobiliary Tumors.","20 Years","50 Years",{"count":179,"type":21},106,[52],"Cancer is a major cause of death and disability worldwide and in South Asian countries. Cancer treatment options include chemotherapy, radiation therapy, surgery, and adjuvant therapy (Additional treatments after primary cancer treatment such as surgery, radiation, or chemotherapy are used to lower the chance of cancer recurrence or remove any remaining cancer cells). Chemotherapy poses serious adverse effects, including fatigue, hair loss, skin irritation, loss of appetite, change in bowel habits, weakened immune system, dry mouth, peripheral neuropathy, nausea and vomiting. Chemotherapy-induced nausea and vomiting cause fluid-electrolyte imbalance, dehydration, weight loss and physiological consequences due to inadequate medication absorption or compromised kidney clearance. Although anti-emetic drugs are given to reduce CINV but these drugs pose some serious adverse effects including heartburn, insomnia, headache, dizziness, constipation\u002Fdiarrhea, loss of muscle control, pharyngeal itching, dry mouth and also increases economic burden on the patient and his\u002Fher family. The limited and hazardous side effects of these medications have led to a shift towards non-pharmacological and home remedies. Using natural remedies is a simple and low-risk measure in this regard. This study aims to evaluate the effects of peppermint oil inhalation on the intensity and frequency of Chemotherapy induced acute nausea and vomiting among cancer patients undergoing chemotherapy. A randomized controlled trial will be conducted using non-probability convenience sampling, followed by random assignment to intervention and control groups. The target population comprises patients receiving chemotherapy at the outpatient oncology department of Jinnah Hospital, Lahore. A total of 106 patients will be enrolled. The intervention group will receive peppermint oil inhalation, while the control group will receive a placebo. Descriptive statistics (frequency, percentage, mean, and standard deviation) will be used to summarize participant's characteristics. Chi-square test will be applied to compare demographic variables (e.g., age, gender, marital status, education, occupation, and RINV categories) between groups. An independent t-test will be used to compare the mean RINV scores post-intervention between intervention and control group. A p-value of \\\u003C0.05 will be considered statistically significant. It is anticipated that peppermint oil inhalation will significantly reduce the severity and frequency of Chemotherapy induced acute nausea and vomiting. If effective, this complementary intervention could offer a low-cost, safe alternative to supplement standard anti-emetic therapies, potentially easing the financial and physiological burden associated with pharmacological treatments.",[153],[184],"Peppermint oil inhalation","2025-04-22",{"date":187,"type":32},"2025-04-30",{"date":189,"type":21},"2025-10-20",{"date":191,"type":21},"2026-03-31",{"name":62,"class":39},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":204,"conditions":205,"keywords":206,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":40},"100581449","phase-3-olanzapine-versus-placebo-for-moderately-emetogenic-chemotherapy-100581449","NCT06850454","Olanzapine Versus Placebo for Moderately Emetogenic Chemotherapy","A Prospective Randomized, Double-blind Controlled Trial of Olanzapine Versus Placebo in Addition to Ondansetron Plus Dexamethasone As Antiemetic Prophylaxis in Patients Receiving Moderately Emetogenic Chemotherapy","Inclusion Criteria:\n\n* histologically confirmed cancer patients who will be started on first dose of oxaliplatin, irinotecan or carboplatin\n* age of \\>18 years old\n\nExclusion Criteria:\n\n* pregnancy or breast feeding\n* has emetic episode within 24 hours\n* gut obstruction\n* uncontrolled brain metastasis\n* allergy to or current use of olanzapine\n* concomittant moderate or high emetogenic chemotherapy on day 2-5\n* Total bilirubin \\> 2 mg\u002Fdl or creatinine clearance \\\u003C 30 ml\u002Fmin\n* unable to swallow drug",{"count":201,"type":21},140,[203],"PHASE3","A study comparing efficacy of olanzapine versus placebo to prevent nausea and vomiting from moderate emetic risk chemotherapy",[153],[207,208,209,210,211],"olanzapine","moderately emetogenic chemotherapy","carboplatin","irinotecan","oxaliplatin","2025-02-21",{"date":214,"type":32},"2025-02-27",{"date":216,"type":32},"2025-01-10",{"date":218,"type":21},"2026-01-31",{"name":220,"class":39},"Mahidol University",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":232,"studyType":233,"phases":4,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":40},"100574187","dolasetron-for-the-prevention-of-cinv-in-children-with-acute-lymphoblastic-leukemia-100574187","NCT06756022","Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia","Prospective, Multicenter, Real-world Study of Dolasetron Mesylate Injection for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children With Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n1. Age 2\\~17 years old\n2. The diagnosis of acute lymphoblastic leukemia was analyzed by comprehensive examination of bone marrow cell morphology, immune typing, cytogenetics and molecular biology.\n3. The subjects plan to receive induced remission therapy such as VDLP\u002FVDLD+CAM, multicenter CCCG ALL 2015 protocol, SCCCG-ALL-2023 protocol, etc. according to Guidelines for Diagnosis and Treatment of Childhood acute lymphoblastic Leukemia (2018 Edition) for the first time\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-2\n5. Expected to survive for more than 3 months\n6. Subject or guardian can read, understand and complete subject diary.\n\nExclusion Criteria:\n\n1. Allergic to Dolasetron mesylate injection and its excipients\n2. Patients with prolonged QTc interval (QT interval ≥460 ms)\n3. Other conditions considered by the researchers not to be included in the group.","2 Years","17 Years",{"count":231,"type":21},500,"1 Week","OBSERVATIONAL","This is a prospective, multicenter, real-world study of 500 participants with childhood acute lymphoblastic leukemia who are scheduled to receive dolasetron mesylate injection for prophylaxis against chemotherapy-induced nausea and vomiting.\n\nThis study did not make any decision or process intervention for clinical antitumor therapy. The study plans to observe the control of nausea and vomiting within 120 h (D1-D5) after receiving induction chemotherapy and the safety within 7 days (or until this discharge, whichever occurs first).\n\nDuring the whole study, demographic data, history of motion sickness, ECOG score, complications, name and dosage of anti-tumor therapy drugs, this antiemetic regimen, nausea and vomiting, rescue therapy drugs, combined drugs and adverse events were recorded.",[153],"2024-12-30",{"date":238,"type":32},"2025-01-01",{"date":240,"type":32},"2024-11-21",{"date":242,"type":21},"2025-12-31",{"name":244,"class":39},"Anhui Provincial Children's Hospital",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":122,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":40},"100517418","phase-3-thalidomide-to-chemotherapy-related-nausea-and-vomiting-in-pancreatic-cancer-100517418","NCT06017284","Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer","PTCA199-5","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document.\n* Age ≥ 18 years and ≤ 80 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Histologically or cytologically confirmed metastatic pancreas adenocarcinoma.\n* Adequate organ performance based on laboratory blood tests.\n* Presence of at least of one measurable lesion in agreement to Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\n* The expected survival ≥ 3 months.\n* Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.\n\nExclusion Criteria:\n\n* Patients who have received any form of anti-tumor therapy.\n* The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas.\n* Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc.\n* Pregnant or nursing women.\n* Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results, including active opportunistic infections or advanced (severe) infections, and diabetes that cannot be controlled after adequate clinical anti-hyperglycemia treatment according to guidelines, uncontrollable hypertension, cardiovascular disease (Class III or IV heart failure as defined by the New York Heart Association classification, congestive heart failure (CHF), myocardial infarction in the past 6 months , unstable arrhythmia or unstable angina, cerebral infarction within 3 months, etc).\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine, nab-paclitaxel, or other agents used in the study.\n* Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.\n* Patients who are unwilling or unable to comply with study procedures.",{"count":253,"type":21},100,[203],"The purpose of this study is to evaluate the efficacy of thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.",[257,27],"Pancreatic Cancer Stage IV",[259,260,261,103,262],"chemotherapy","pancreatic cancer","Thalidomide","quality of life","2023-11-21",{"date":265,"type":32},"2023-11-24",{"date":267,"type":32},"2023-11-01",{"date":269,"type":21},"2026-11-30",{"name":271,"class":39},"Fudan University",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":286,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":40},"100503944","phase-4-efficacy-and-safety-of-intravenous-versus-oral-5-ht3-antagonists-combined-with-nk-1-receptor-antagonists-for-the-prevention-of-cinv-in-breast-cancer-100503944","NCT05841849","Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer","Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of Breast Cancer Chemotherapy-induced Nausea and Vomiting: a Single-center, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Female, age 18-70 years.\n* Confirmed pathology suggested primary invasive breast adenocarcinoma; Presence of adjuvant chemotherapy or neoadjuvant chemotherapy indications according to clinical guidelines.\n* No other malignant tumor or other chemotherapy\n* No prior treatment for present breast cancer onset\n* ECOG physical status score 0 to 1\n* Hematological examination before treatment should meet: white blood cell count (WBC) ≥ 4.0×10\\^9\u002FL, neutrophil count (ANC) ≥ 1.5×10\\^9\u002FL, platelet count (PLT) ≥ 100×10\\^9\u002FL; hemoglobin (Hb) ≥ 90g\u002FL; AST (sGOT), ALT (sGPT) ≤ 1.5 times the normal value upper limit, creatinine ≤ 1.5 times the upper limit of normal value, total bilirubin ≤ 1.5 times the upper limit of normal value.\n* No serious impairment of heart, liver, kidney and other important organ functions.\n\nExclusion Criteria:\n\n* Unwilling or unable to use an acceptable method of contraception for up to and including 8 weeks after the final dose of the test drug.\n* Women during pregnancy and breastfeeding after pregnancy.\n* Women with proven distant metastases of breast cancer.\n* Patients with proven sensory or motor nerve disease.\n* Definite cardiovascular disease, severe co-morbidity or active infection, including known HIV infection.\n* Patients who need long-term anticoagulant drugs for cardiovascular or thrombotic diseases.\n* History of other tumors.\n* Allergic to the study drug or its excipients, etc.","70 Years",{"count":281,"type":21},1028,[24],"Chemotherapy is one of the most common treatments for breast cancer, but the adverse effects can be severe enough to delay or make chemotherapy intolerable, thus affecting the efficacy of the disease. Women and younger patients are more likely to experience chemotherapy-induced nausea and vomiting (CINV) . Therefore, antiemetic drugs is a key way to reduce chemotherapy side effects, which ensures compliance, and maintain quality of life. CINV is usually induced by two pathways. The central pathway is mediated by neurokinin-1 (NK-1) receptors, where chemotherapeutic agents stimulate the secretion of substance-P (SP) from the vomiting center located in the medulla oblongata and nucleus accumbens, which binds to NK-1 receptors and induces vomiting. The peripheral pathway is mediated by 5-hydroxytryptamine 3 (5-HT3) receptors, and chemotherapy stimulates intestinal chromophores in the gastrointestinal mucosa to secrete 5-HT3, which binds to its receptors to induce vomiting.\n\nMost guidelines currently recommend the combination of 5-HT3 receptor antagonists, NK-1 receptor antagonists, and dexamethasone for high-emetogenic-risk chemotherapy regimens. Usually 5-HT3 receptor antagonists include granisetron, ondansetron, and palonosetron. Palonosetron is a second-generation 5-HT3 receptor antagonist with stronger affinity and higher efficacy than other antagonists. The commonly used NK-1 receptor antagonists are aprepitant and fosaprepitant. Fosaprepitant is an aprepitant prodrug that can be rapidly converted to aprepitant in the body, blocking the binding of substance P to NK-1 receptors for antiemetic purposes. Clinical trial has confirmed that the overall complete response (CR) rate of palonosetron 0.75 mg combined with fosaprepitant and dexamethasone was 54.9%, with 75.9% CR in the acute phase (0-24 h after chemotherapy) and 62.3% in the delayed phase (24-72 h after chemotherapy). Another clinical trial showed an acute phase CR of 89.8% and a delayed phase CR of 90.4% for oral aprepitant combined with intravenous palonosetron 0.75 mg and dexamethasone. The data suggests that both oral and intravenous administration are effective in preventing CINV, but there are no clinical trial results for oral versus intravenous administration. Oral administration is painless, has fewer side effects, and is a safer mode of administration, but bioavailability is different and drug absorption is affected by a variety of factors; whereas intravenous injection has rapid onset of action, but there are risks of injection reactions, phlebitis, and infection. Therefore, we hope to conduct a non-inferiority study on the efficacy of oral and intravenous 5-HT3 receptor antagonists combined with NK-1 receptor antagonists through this trial, which can provide more options for patients by combining the cost and administration methods.",[285,27],"Breast Cancer",[287,288,259,289],"breast cancer","CINV","oral versus intravenous","2023-04-23",{"date":292,"type":32},"2023-05-03",{"date":294,"type":21},"2023-07",{"date":296,"type":21},"2029-07",{"name":298,"class":39},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]